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Abstract
Background: West Nile virus (WNV) has emerged as one of the most common causes of epidemic meningoencephalitis
worldwide. Most human infections are asymptomatic. However, neuroinvasive disease characterized by meningitis,
encephalitis and/or acute flaccid paralysis is associated with significant morbidity and mortality. Although outbreaks have
been reported in Asia, human WNV infection has not been previously reported in Sri Lanka.
Methods: Sera and cerebrospinal fluid (CSF) from 108 consecutive patients with a clinical diagnosis of encephalitis
admitted to two tertiary care hospitals in Colombo, Sri Lanka were screened for WNV IgM antibody using enzyme-linked
immunosorbent assay. Positive results were confirmed using plaque reduction neutralization test (PRNT). Patient data
were obtained from medical records and by interviewing patients and care-givers.
Results: Three of the 108 patients had WNV IgM antibody in serum and one had antibody in the CSF. The presence of
WNV neutralizing antibodies was confirmed in two of the three patients using PRNT. Two patients had presented with
the clinical syndrome of meningoencephalitis while one had presented with encephalitis. One patient had CSF
lymphocytic pleocytosis, one had neutrophilic pleocytosis while CSF cell counts were normal in one. CSF protein showed
marginal increase in two patients.
Conclusions: This is the first report of human WNV infection identified in patients presenting with encephalitis or
meningoencephalitis in Sri Lanka. There were no clinical, routine laboratory or radiological features that were
distinguishable from other infectious causes of meningoencephalitis.
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Background
West Nile virus (WNV) is one of the most widely dis-
tributed, medically important arboviral infections that
has caused major outbreaks in many parts of the world
[1]. Although the initial WNV outbreaks were confined
to rural areas in Africa [1], it is now the leading cause of
encephalitis in USA, Europe and Australia [2, 3]. Initial
WNV outbreaks were associated with only a few cases
of severe neurological diseases. However, neuroinvasive
disease is now more frequent and the case fatality rates
range from 4.2 to 18.6 % in more recent epidemics [1, 4, 5].
WNV is considered to be one of the most important
emerging flaviviral infections in the world, due to the
increase in the number of cases with expansion in geo-
graphical distribution, and its association with severe
neurological disease [6, 7].
WNV is a zoonotic infection, where the virus cycles
between mosquitoes and birds. The Culex genus of mos-
quitoes are the main vectors while passerine birds act as
amplifying hosts [1]. Humans and mammals are usually
incidental, dead-end hosts as viral titers in mammals are
insufficient to infect mosquitoes for further transmission
to other mammals [8]. WNV results in neuroinvasive
disease in less than 1 % (approximately 1 in 150) of in-
fected individuals, while asymptomatic infections occur
in around 80 % [9, 10]. Approximately 20 % of infected
individuals develop WN fever, which is an undifferenti-
ated flu-like illness that occurs 2–14 days after an infec-
tious mosquito bite. This is characterized by fever,
myalgia, gastrointestinal symptoms and sometimes a
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macular-papular rash [9]. WN fever may mimic the clin-
ical syndromes of other flavivirus infections such as den-
gue fever. WNV neuroinvasive disease manifests as
meningitis, encephalitis, asymmetric acute flaccid paralysis
or a mixed pattern of these syndromes. Encephalitis is
more common than meningitis in older age groups, and is
commonly associated with extrapyramidal features while
acute flaccid paralysis may lead to respiratory paralysis.
After the acute infection, many patients experience per-
sistent symptoms, such as fatigue, memory impairment,
weakness, headache, and balance problems.
Encephalitis is a notifiable disease in Sri Lanka and an-
nually, 165–220 cases are reported to the Epidemiology
Unit of Sri Lanka. However, in 2013, a large outbreak of
encephalitis occurred with 141 cases of encephalitis be-
ing reported in the first 2 months of the year. Although
cases of encephalitis occur throughout the year in Sri
Lanka, there are usually two peaks in the number of
cases reported (Fig. 1) [11–13]. These peaks coincide
with the monsoon rain seasons in Sri Lanka and are
likely to reflect an increase in vector densities caused by
increased mosquito breeding in stagnant collections of
rainwater. These two peaks also coincide with the latter
part of the migratory bird season. This provides the
requisite environment for the maintenance of the zoo-
notic WNV life-cycle between mosquitoes and birds.
The Culex genus of mosquitoes are endemic while pas-
serine birds are both endemic and migratory in Sri
Lanka. Although human WNV infection has not been
previously reported in Sri Lanka, it has reportedly
caused several outbreaks in neighboring India, including
Kerala and Tamil Nadu, which are in close proximity to
Sri Lanka [14, 15].
Given the conducive environment for transmission,
WNV has the potential to emerge as a major cause of
meningoencephalitis in Sri Lanka. In this study, we report
the first identification of human WNV infection in Sri
Lanka in patients presenting with meningoencephalitis.
Methods
Patients
108 patients with clinical syndromes of encephalitis or
meningoencephalitis, who were admitted to two of the
largest tertiary care hospitals in Sri Lanka (the National
Hospital of Sri Lanka and the Lady Ridgeway Hospital
for Children), were included in the study following in-
formed written consent. In the instances where children
were recruited, informed written consent was obtained
from the guardian. The study was approved by the Ethic
Review Committees of the Faculty of Medicine, Univer-
sity of Colombo and those of the two hospitals. Clinical
and laboratory data including cerebrospinal fluid (CSF)
analysis, CT or MRI scan results were recorded. Serum
and CSF were obtained from all patients and stored at
-80 °C until analyzed.
ELISA for detection of WNV
WNV Detect™ IgM enzyme-linked immunosorbent assay
(ELISA) (InBios, USA) was used for the initial screening
for WNV infection. In sera and CSF that tested positive
for WNV, ELISA for Japanese encephalitis virus (JEV)
and dengue virus were also performed to eliminate po-
tential false positive results due to the cross-reactivity
between the antibodies of these flaviviruses. JE Detect™
IgM ELISA (InBios, USA) was used for the detection of
antibodies in human serum to determine exposure to
JEV. Calculation of the immune status ratio (ISR) was
done according to the manufacturer’s instructions that
consider ISR units of > 6.0 as positive for acute JEV infec-
tion. Serum and CSF were also tested for the presence of
anti-dengue virus antibodies by using a commercial
capture-IgM and IgG ELISA (Panbio, Brisbane, Australia).
Panbio units of > 11 were considered positive for acute
dengue infection.
Plaque reduction neutralization test (PRNT) for WNV
PRNT was done at the National West Nile virus refer-
ence laboratory of the National University of Singapore.
Serum samples were inactivated at 56 °C for 30 min, and
diluted 100 times in RPMI medium containing 2 % FBS
(virus diluent). A 10-step 2-fold serial dilution was car-
ried out using virus diluent before 500 PFU of WNV
was added to 500 μl of each serum dilution. The rest of
the assay was performed as previously described [16].
WNV specific RT-PCR
Viral RNA was extracted from serum using QIAmp viral
RNA mini kit (Qiagen, Germany). RNA was reverse
transcribed and the PCR was performed by using primer
and conditions as previously described [17].
Fig. 1 Temporal distribution of notified cases of encephalitis in Sri
Lanka. Arrows indicate peak periods of highest frequencies reported
during the year
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Laboratory criteria for diagnosis of WNV infection
WNV infection was diagnosed as ‘definite’ in patients
with WNV-specific IgM in serum or CSF (detected
using ELISA) and confirmed with the WNV-specific
PRNT assay. WNV infection was diagnosed as ‘probable’
in patients with WNV-specific IgM in serum or CSF, but
without JEV or dengue virus IgM (detected using ELISA)
in the absence of WNV-specific PRNT confirmation.
Results
Of the 108 patients recruited into the study, 3 were diag-
nosed to have WNV neuroinvasive disease based on
their clinical syndromes and confirmed by laboratory re-
sults (Table 1). WNV IgM antibodies were detected in
the serum of all three patients and the CSF of Patient
#2. CSF of the other two patients could not be tested
due to insufficient quantities of CSF. Because antibodies
to JEV and dengue virus can cross-react and give rise to
false-positive results in the WNV IgM ELISA test [18,
19], we tested both sera and CSF for the presence of
JEV-specific IgM antibodies and dengue virus-specific
IgM and IgG antibodies. Cross-reactivity was evident in
Patients #1 and #2 (Table 1). None of the samples tested
positive for WNV on RT-PCR. In order to confirm
WNV infection, the seropositive sera of Patients #1 and
#2 were analysed for the presence of neutralizing anti-
bodies to WNV, using the PRNT assay. Both patients
had PRNT50 neutralizing antibody titers of 800 against
WNV. Accordingly, Patients #1 and #2 were diagnosed
to have definite WNV infection while Patient #3 was di-
agnosed to have probable WNV infection.
The clinical and laboratory features of these patients
are shown in Table 2. Two were males and one female,
with ages ranging from 17 to 49 years. All three patients
presented with abrupt onset fever and altered sensorium,
predominantly confusion. Patients #2 and #3 had
prominent headache, and Patients #1 and #3 developed
generalised tonic-clonic seizures. Neck rigidity and in-
creased tone was noted in Patients #2 and #3. Neutrophil
leucocytosis was noted in the peripheral blood of two pa-
tients. Lymphocytic pleocytosis was noted in the CSF of
one patient while neutrophils predominated in the CSF of
Patient #2. CSF analysis was normal in Patient #1. CSF
protein was marginally elevated in two of the three pa-
tients. Generalised cerebral oedema was noted in Patients
#2 and #3 on CT brain imaging. MRI brain was done in
only Patient #3 which showed meningeal enhancement.
All three patients were treated with empirical intravenous
antibiotics and aciclovir for variable periods and all pa-
tients recovered to their pre-morbid states.
Discussion
This is the first report of human WNV infection in Sri
Lanka presenting with encephalitis and meningoenceph-
alitis. Three of 108 patients (2.8 %) presenting with a
clinical diagnosis of encephalitis or meningoencephalitis
admitted to hospital were diagnosed to have WNV in-
fection retrospectively when serum and CSF were
screened for WNV IgM antibodies. Since dengue and
Japanese encephalitis are endemic in Sri Lanka and anti-
flavivirus antibodies may cross-react in ELISA to give
false-positive results, WNV infection in Patients #1 and
#2 were confirmed by specific PRNT assay.
Detection of WNV-specific IgM antibodies in serum and
CSF remains the gold standard for the diagnosis of human
WNV disease. IgM antibodies to WNV are usually detect-
able by ELISA in 75 % by day 4 post-infection and 95 % by
day 7 post-infection in WNV infected patients [20]. Since
IgM antibodies do not readily cross the blood brain barrier,
detection of WNV IgM in CSF is diagnostic of neuroinva-
sive disease. WNV IgM antibody was detected in the CSF
in Patient #2. However, unlike most IgM responses, WNV
IgM antibody can persist for 6 months or longer in both
serum and CSF [21]. The PRNT is the most specific diag-
nostic test for WNV and can help distinguish serologic
cross-reactions caused by other flaviviruses. However, this
test is not commercially available, is tedious, and can only
be performed in laboratories with the relevant capabilities.
Nucleic acid amplification for viral detection is highly spe-
cific, but is of limited sensitivity (less than 15 % for serum)
since viraemia occurs early before the onset of symptoms,
is of low titer and is short-lived [22].
Peripheral blood counts can be normal in patients with
WNV neuroinvasive disease, or can demonstrate anaemia,
thrombocytopenia, leukocytosis or leukopenia [20]. Typical
CSF findings in WNV neuroinvasive disease include
moderate lymphocytic pleocytosis (usually <500 cells/μl)
with elevated protein (usually <150 mg/dl) and slightly
low or normal levels of glucose [23]. However, neutrophils
may predominate in early infection in up to 45 % of
Table 1 Results of IgM-ELISA of West Nile, Japanese encephalitis
and dengue virus in serum and CSF of the reported patients
Patient #1 Patient #2 Patient #3
WNV Serum 35.343 23.433 7.032
WNV CSF ND 37.518 ND
JEV Serum 12.656 31.100 1.308
JEV CSF 1.746 29.344 ND
Dengue Serum 49.051 4.642 8.825
Dengue CSF 8.204 11.211 ND
PRNT value for WNV
Cut off values for WNV antibodies: positive >5.66; equivocal 4.47–5.66;
negative <4.47
Cut off values for JEV antibodies: positive >6.00; equivocal 4.00–6.00;
negative <4
Cut off values for Dengue antibodies: positive >11; equivocal 9–11;
negative <9
CSF cerebrospinal fluid, JEV Japanese encephalitis virus, ND not done, WNV
West Nile virus
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Table 2 Clinical and laboratory features of the reported patients
Patient #1 Patient #2 Patient #3
Age (years) and sex 17, male 36, female 49, male
Clinical presentation
Fever + (high grade, 3 days) + (high grade, 3 days) + (high grade, 5 days)
Headache - + (severe, 3 days) + (5 days)
Nausea/vomiting - + +
Altered level of consciousness + (confusion) + (confusion) + (agitation, 5 days)
Seizures 2 x GTCS - 2 x GTCS
Other Asthenia, polyarthralgia Photophobia -
Past medical history Nil Nil Hypertension
Neurological examination GCS 14/15; confused; no focal
signs, neck stiffness or paralysis;
normal cranial nerves and tendon
reflexes.
GCS 11/15; neck stiffness and
increased limb tone; normal
tendon reflexes; no focal signs;
disconjugate gaze but otherwise
normal cranial nerves.
GCS 10/15; neck stiffness;
increased limb tone and
tendon reflexes.
General and other systems examination Normal; no rash; BP 110/70 mmHg Normal; no rash; BP 100/60 mmHg No rash; BP 140/90 mmHg
Blood investigations
Haemoglobin (g/dl) 14.8 10.5 14.3
White cell count (x 109/L) 5,400 12,200 N85% 13,200
Platelet count (x 109/L) 154,000 235,000 263,000
ESR (mm/h) Not done Not done 03
CRP (mg/L) ND 96 ND
ALT (U/L) 46 ND 106
AST (U/L) 85 ND 156
SAP (U/L) 221 ND 157
Creatinine (μmol/L) 60 ND 66
Sodium (mmol/l) 140 ND 118
Potassium (mmol/l) 3.9 ND 3.9
Cerebrospinal fluid
Colour Colourless Colourless Colourless
Protein (mg/dl) 42 48 26
Glucose 4.3 2.2 2.7
Lymphocytes 01 00 10
Polymorphs 00 64 02
Erythrocytes 01 32 3500
Gram stain Negative Negative Negative
Culture Negative Negative Negative
Other PCR TB: negative
Random plasma glucose (mmol/l) 6.5 4.5 8.1
Neuroimaging
CT brain Normal Cerebral oedema Cerebral oedema
MRI brain Not done Not done Meningeal enhancement
EEG Bilateral slow wave discharges Bilateral slow wave discharges Bilateral slow wave discharges
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patients, while 3–5 % of patients with meningitis or en-
cephalitis may have normal CSF cell counts [23]. The pres-
ence of abnormalities on neuroimaging has been variable
ranging from none to 70 % of reported cases [20].
Of the three patients reported here, two (Patient #2
and #3) presented with clinical features of meningo-
encephalitis while one presented with encephalitis indis-
tinguishable from other infectious aetiologies presenting
with similar syndromes. Although the association of
extrapyramidal features and flaccid paralysis is reported
to be common in WNV neuroinvasive disease [20], our
patients did not demonstrate such distinguishing clinical
characteristics. Of the two patients who had peripheral
neutrophil leucocytosis, in Patient #3, it is likely to be
related to seizures given that the inflammatory marker
(ESR) was normal. Bacteriological screening of all three
patients, which included blood culture and CSF Gram
stain and culture, were negative. The presence of neutro-
phil predominance in CSF has been suggested as a pos-
sible diagnostic clue of WNV infection [23], but only
Patient #2 of our three patients had CSF neutrophilic
pleocytosis.
Conclusion
In summary, the clinical, routine laboratory or radio-
logical features of our patients did not provide any diag-
nostic clues of WNV infection; diagnosis was established
based on serological testing for WNV and excluding
other possible aetiologies. It is thus reasonable that all
patients presenting with a clinical syndrome of meningi-
tis, encephalitis, asymmetric acute flaccid paralysis or
any combination of these three syndromes be screened
for WNV IgM since this report has now established the
occurrence of human WNV disease in Sri Lanka. An ac-
curate diagnosis will help avoid inappropriate treatment
and allow correct prognostication. Moreover, this will
enable timely evaluation of possible outbreaks of a
vector-borne disease that has the potential to emerge as
a major cause of meningoencephalitis as it has done in
other WNV endemic countries such as the United States
of America. This will also allow the Sri Lankan public
health authorities to institute timely preventive mea-
sures. By extrapolating that neuroinvasive disease occurs
in 1 in 150 to 1 in 250 WNV infections [24], our report
of three cases would imply that there would be between
450 and 750 cases of WNV infection. As our sample in-
cluded only patients admitted to two major hospitals in
Colombo, Sri Lanka, and since it did not include pa-
tients presenting with acute flaccid paralysis, the actual
number of WNV infections is likely to be much higher
than our estimate.
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